FDA approves zipalertinib for EGFR exon 20 insertion NSCLC after platinum-based chemotherapy on or before the disclosed PDUFA goal date of 2027-02-27

The proposition

What was registered

The FDA takes an approval action on the New Drug Application for zipalertinib (Taiho Oncology, developed with Cullinan Therapeutics) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with an approval action date on or before 2027-02-27, the PDUFA target action date disclosed in Exhibit 99.1 to Cullinan Therapeutics’ Form 8-K filed 2026-08-06.

Who decides

US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (US)

Decision stageThe kind of body that has to act: a guideline panel, a regulator, or a payer. The ladder, rung by rung

Rung 6: Regulatory action — Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.

Decision typeThe type of decision this forecast is counted with, such as FDA actions by their goal dates

FDA action by goal date

Scope

EGFR exon 20 insertion NSCLC after platinum-based chemotherapy

The clock

Dates that constrain the record

Evidence as of

2026-10-21
Nothing after this date informed the estimate.

Registered

2026-11-04
Frozen and hashed.

Reading window

2026-10-22 → 2027-02-27
When the outcome can be read against the rule.

Event by

2027-02-27
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar

Resolution

The rule that settles the forecast

The application number was not public at the cutoff, and openFDA held no record for the ingredient (SRC-006, SRC-007). The adjudicator identifies the qualifying approval by its indication plus its ingredient, never by a name the adjudicator infers: an approval action whose Drugs@FDA approval letter or label names non-small cell lung cancer with EGFR exon 20 insertion mutations in patients previously treated with platinum-based chemotherapy in its indication, for a product whose active ingredient is zipalertinib (CLN-081, TAS6417) or a salt of it, under any applicant (Taiho Oncology, Taiho Pharmaceutical or another Taiho or Otsuka affiliate) and any proprietary name. Resolves YES if the openFDA Drugs@FDA records returned by https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22ZIPALERTINIB%22&limit=100 and by https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22zipalertinib%22&limit=100, read together (openFDA does not always fill the generic-name field for a new application), contain such an approval: an application whose ORIG submission has submission_status AP and a submission_status_date on or before 2027-02-27. Accelerated rather than traditional approval resolves YES, as does an indication narrower than the applicant sought within that previously treated population (for example, limited to patients not previously treated with amivantamab). An approval only for first-line use with chemotherapy, the separate submission begun on 2026-10-01 (SRC-005), does not count and resolves partial_nonqualifying. Resolves NO if no qualifying approval action is dated on or before 2027-02-27: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2027-02-27 resolves NO as occurred_after_deadline. 2027-02-27 is a Saturday; an approval action dated that day still counts. Read no earlier than 2027-03-13. If openFDA has not refreshed by then, or both queries return nothing, the Drugs@FDA web record (https://www.accessdata.fda.gov/scripts/cder/daf/, searched by the name zipalertinib) governs, under the same identification test. Resolves unresolvable only if none of these sources can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.

Source the rule names: https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22zipalertinib%22&limit=100, https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22ZIPALERTINIB%22&limit=100, https://www.accessdata.fda.gov/scripts/cder/daf/

Readers: Resolver A, clinical methodology; Resolver B, payer evidence. The same two reader roles are assigned to every forecast registered so far.

What this record will show once it resolves

Frozen covariatesThe facts about the evidence and the authority's process that were frozen with the forecast at its cutoff

The state of the record at the cutoff

Recorded as they stood on 2026-10-21.

review pathway

Standard review, inferred from the timing: rolling NDA completed February 2026, accepted April 2026, goal date 2027-02-27 (SRC-002, SRC-003); seeking accelerated approval (SRC-003, SRC-005). Breakthrough Therapy designation since 2022 (SRC-003). Center CDER is the drafter’s understanding (a small-molecule NDA), unverified.

submission type

Original NDA for zipalertinib (SRC-001, SRC-002); application number not public, and openFDA holds no record for the ingredient (SRC-006, SRC-007).

evidence class

Single-arm pivotal phase 2b portion of REZILIENT1 (SRC-003); supported by the randomized phase 3 REZILIENT3 in first line, which met its PFS primary endpoint at a planned interim analysis (SRC-004).

pivotal n

125 patients previously treated with chemotherapy only, plus 84 after amivantamab with or without other exon 20 targeted therapy (SRC-003)

endpoint type

Surrogate: confirmed objective response rate and duration of response (SRC-003).

approved competitors in class

Two companies have FDA-approved therapies for EGFR exon 20 insertion NSCLC, Johnson & Johnson and Dizal Pharmaceutical (SRC-003).

months since last guideline revision

not applicable — no guideline is the subject of this proposition

panel cycle position

not applicable — the act is an FDA approval action

sponsor request status

NDA accepted April 2026 with a PDUFA target action date of 2027-02-27 (SRC-001, SRC-002); restated as under review on 2026-10-01 (SRC-005).

odac referral

none announced in the archived sources

sponsor state change

REZILIENT3 met its primary endpoint at a planned interim analysis, with results presented 2026-09-13 (SRC-004); a first-line NDA submission under Real-Time Oncology Review was initiated 2026-10-01, completion expected by year-end 2026 (SRC-005).